Menu

To set up a press or media interview with this expert contact:

Charles Margulis

Email: charles.margulis@phi.org
Cell: 510-560-3657

Biography

S. Brooke Briggance comes from a multi-sector background in health, direct impact programming for children, youth and families, and non-profit work. She began her career in healthcare in the Department of Neurology at SUNY Stony Brook in New York, and has experience in administrative leadership and public education advocacy and reform. She served as the Executive Director of an education foundation and has worked as a consultant assisting in projects ranging from school district redesign, community engagement and best practices for non-profits.

She currently serves as the Program Director for the Cypress Resilience Project and as Deputy Director for the FACES for the Future Coalition – both programs at Public Health Institute in Oakland, CA. Brooke has a B.A. in World Religions and Comparative Religions from SUNY Stony Brook. She is a Certified Grief Recovery Specialist, a Certified Mental Health First Aid Instructor (Adult, Youth and Teen Curricula), and a Certified Trainer in Trauma Informed Systems and Practice. Originally from Michigan, she moved to California in 1999.

See How S. Brooke Briggance Contributed to Our Impact

Work With Us

You change the world. We do the rest. Explore fiscal sponsorship at PHI.

Bring Your Work to PHI

Support Us

Together, we can accelerate our response to public health’s most critical issues.

Donate

Find Employment

Begin your career at the Public Health Institute.

See Jobs

Close

Breakthrough Infection Study of Over 600,000 Veterans Shows Declining COVID-19 Vaccine Protection

A new pre-print study of over 600,000 veterans by researchers from PHI and the Veterans Affairs Medical Center finds that overall COVID-19 vaccine protection declined significantly between February and August 2021. Declines were greatest for the Johnson & Johnson vaccine (from 88% in March to 3% in August), followed by PfizerBioNTech (91% to 50%) and Moderna (92% to 64%).

More

Continue to PHI.org